Rise Advisors’s RAPT Therapeutics RAPT Stock Holding History

Rise Advisors’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-54	Closed	-$531	–	1624
2025 Q1	$531	Buy	+54	New	+$531	﹤0.01%	1363

Other funds holding RAPT

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Rise Advisors's RAPT Position: Q2 2025 in Review

Rise Advisors sold out of RAPT Therapeutics (RAPT) in Q2 2025, closing a stake of 54 shares — an estimated $531 sold.

Rise Advisors first reported a position in RAPT in Q1 2025 and held it in 1 quarter. The position peaked at $531 in Q1 2025. 50 funds tracked by Wall St. Rank hold RAPT as of Q2 2025.

Rise Advisors reported no remaining RAPT Therapeutics position as of Q2 2025 after selling out during the quarter.
Rise Advisors sold 54 RAPT Therapeutics shares in Q2 2025, an estimated $531.
Rise Advisors first reported a position in RAPT Therapeutics in Q1 2025 and held it in 1 quarter.
Rise Advisors's RAPT Therapeutics position peaked at $531 in Q1 2025.
50 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2025.

Based on Rise Advisors's 13F filing for Q2 2025, filed 8 Jul 2025.